DelveInsight's "Age Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Age Related Macular Degeneration, historical and forecasted epidemiology as well as the Age Related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Age Related Macular Degeneration market report provides current treatment practices, emerging drugs, Age Related Macular Degeneration market share of the individual therapies, current and forecasted Age Related Macular Degeneration market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Age Related Macular Degeneration treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Age Related Macular Degeneration market.
Study Period: 2019-2032
The DelveInsight’s Age Related Macular Degeneration market report gives a thorough understanding of the Age Related Macular Degeneration by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.
Age Related Macular Degeneration Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Age Related Macular Degeneration.
Age Related Macular Degeneration Treatment
It covers the details of conventional and current medical therapies available in the Age Related Macular Degeneration market for the treatment of the condition. It also provides Age Related Macular Degeneration treatment algorithms and guidelines in the United States, Europe, and Japan.
The Age Related Macular Degeneration epidemiology section provides insights about the historical and current Age Related Macular Degeneration patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Age Related Macular Degeneration market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Age Related Macular Degeneration epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Age Related Macular Degeneration Epidemiology
The epidemiology segment also provides the Age Related Macular Degeneration epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The drug chapter segment of the Age Related Macular Degeneration report encloses the detailed analysis of Age Related Macular Degeneration marketed drugs and late-stage (Phase-III and Phase-II) Age Related Macular Degeneration pipeline drugs. It also helps to understand the Age Related Macular Degeneration clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Age Related Macular Degeneration Marketed Drugs
The report provides the details of the marketed products/off-label treatments available for Age Related Macular Degeneration treatment.
Age Related Macular Degeneration Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Age Related Macular Degeneration treatment.
The Age Related Macular Degeneration market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Age Related Macular Degeneration market trends by analyzing the impact of current Age Related Macular Degeneration therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Age Related Macular Degeneration market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Age Related Macular Degeneration market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Age Related Macular Degeneration market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
This section includes a glimpse of the Age Related Macular Degeneration market in 7MM.
The United States Market Outlook
This section provides the total Age Related Macular Degeneration market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Age Related Macular Degeneration market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Age Related Macular Degeneration market size and market size by therapies in Japan is also mentioned.
This section focuses on the rate of uptake of the potential Age Related Macular Degeneration drugs recently launched in the Age Related Macular Degeneration market or expected to get launched in the market during the study period 2019-2032. The analysis covers Age Related Macular Degeneration market uptake by drugs; patient uptake by therapies; and sales of each drug.
Age Related Macular Degeneration Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Age Related Macular Degeneration market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Age Related Macular Degeneration Pipeline Development Activities
The Age Related Macular Degeneration report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Age Related Macular Degeneration key players involved in developing targeted therapeutics.
Pipeline Development Activities
The Age Related Macular Degeneration report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Age Related Macular Degeneration emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current Age Related Macular Degeneration market trends, we take KOLs and SMEs ' opinion working in the Age Related Macular Degeneration domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Age Related Macular Degeneration market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Age Related Macular Degeneration Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
1. Key Insights
2. Executive Summary of Age Related Macular Degeneration
3. Competitive Intelligence Analysis for Age Related Macular Degeneration
4. Age Related Macular Degeneration: Market Overview at a Glance
4.1. Age Related Macular Degeneration Total Market Share (%) Distribution in 2019
4.2. Age Related Macular Degeneration Total Market Share (%) Distribution in 2032
5. Age Related Macular Degeneration: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Age Related Macular Degeneration Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Age Related Macular Degeneration Epidemiology Scenario in the 7MM (2019-2032)
7.4. United States Epidemiology
7.4.1. Age Related Macular Degeneration Epidemiology Scenario in the United States (2019-2032)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Age Related Macular Degeneration Epidemiology Scenario in Germany (2019-2032)
7.5.2. France Epidemiology
7.5.2.1. Age Related Macular Degeneration Epidemiology Scenario in France (2019-2032)
7.5.3. Italy Epidemiology
7.5.3.1. Age Related Macular Degeneration Epidemiology Scenario in Italy (2019-2032)
7.5.4. Spain Epidemiology
7.5.4.1. Age Related Macular Degeneration Epidemiology Scenario in Spain (2019-2032)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Age Related Macular Degeneration Epidemiology Scenario in the United Kingdom (2019-2032)
7.5.6. Japan Epidemiology
7.5.6.1. Age Related Macular Degeneration Epidemiology Scenario in Japan (2019-2032)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Age Related Macular Degeneration Treatment and Management
8.2. Age Related Macular Degeneration Treatment Algorithm
9. Age Related Macular Degeneration Unmet Needs
10. Key Endpoints of Age Related Macular Degeneration Treatment
11. Age Related Macular Degeneration Marketed Products
11.1. List of Age Related Macular Degeneration Marketed Drugs in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Age Related Macular Degeneration Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Age Related Macular Degeneration: Seven Major Market Analysis
13.1. Key Findings
13.2. Age Related Macular Degeneration Market Size in 7MM
13.3. Age Related Macular Degeneration Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Age Related Macular Degeneration Total Market Size in the United States
15.1.2. Age Related Macular Degeneration Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Age Related Macular Degeneration Total Market Size in Germany
15.3.2. Age Related Macular Degeneration Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Age Related Macular Degeneration Total Market Size in France
15.4.2. Age Related Macular Degeneration Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Age Related Macular Degeneration Total Market Size in Italy
15.5.2. Age Related Macular Degeneration Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Age Related Macular Degeneration Total Market Size in Spain
15.6.2. Age Related Macular Degeneration Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Age Related Macular Degeneration Total Market Size in the United Kingdom
15.7.2. Age Related Macular Degeneration Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Age Related Macular Degeneration Total Market Size in Japan
15.8.3. Age Related Macular Degeneration Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Age Related Macular Degeneration
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
*The table of contents is not exhaustive; the final content may vary.
List of Table
Table 1: 7MM Age Related Macular Degeneration Epidemiology (2019-2032)
Table 2: 7MM Age Related Macular Degeneration Diagnosed and Treatable Cases (2019-2032)
Table 3: Age Related Macular Degeneration Epidemiology in the United States (2019-2032)
Table 4: Age Related Macular Degeneration Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Age Related Macular Degeneration Epidemiology in Germany (2019-2032)
Table 6: Age Related Macular Degeneration Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Age Related Macular Degeneration Epidemiology in France (2019-2032)
Table 8: Age Related Macular Degeneration Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Age Related Macular Degeneration Epidemiology in Italy (2019-2032)
Table 10: Age Related Macular Degeneration Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Age Related Macular Degeneration Epidemiology in Spain (2019-2032)
Table 12: Age Related Macular Degeneration Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Age Related Macular Degeneration Epidemiology in the UK (2019-2032)
Table 14: Age Related Macular Degeneration Diagnosed and Treatable Cases in the UK (2019-2032)
Table 15: Age Related Macular Degeneration Epidemiology in Japan (2019-2032)
Table 16: Age Related Macular Degeneration Diagnosed and Treatable Cases in Japan (2019-2032)
Table 17: Drug Name, Clinical Trials by Recruitment status
Table 18: Drug Name, Clinical Trials by Zone
Table 19: Total Seven Major Market Size in USD, Million (2019-2032)
Table 20: Region-wise Market Size in USD, Million (2019-2032)
Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
Table 22: United States Market Size in USD, Million (2019-2032)
Table 23: United States Market Size by Therapy in USD, Million (2019-2032)
Table 24: Germany Market Size in USD, Million (2019-2032)
Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)
Table 26: France Market Size in USD, Million (2019-2032)
Table 27: France Market Size by Therapy in USD, Million (2019-2032)
Table 28: Italy Market Size in USD, Million (2019-2032)
Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)
Table 30: Spain Market Size in USD, Million (2019-2032)
Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)
Table 32: United Kingdom Market Size in USD, Million (2019-2032)
Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
Table 34: Japan Market Size in USD, Million (2019-2032)
Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)
*The list of tables is not exhaustive; the final content may vary
List of Figures
Figure 1: 7MM Age Related Macular Degeneration Epidemiology (2019-2032)
Figure 2: 7MM Age Related Macular Degeneration Diagnosed and Treatable Cases (2019-2032)
Figure 3: Age Related Macular Degeneration Epidemiology in the United States (2019-2032)
Figure 4: Age Related Macular Degeneration Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5: Age Related Macular Degeneration Epidemiology in Germany (2019-2032)
Figure 6: Age Related Macular Degeneration Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7: Age Related Macular Degeneration Epidemiology in France (2019-2032)
Figure 8: Age Related Macular Degeneration Diagnosed and Treatable Cases in France (2019-2032)
Figure 9: Age Related Macular Degeneration Epidemiology in Italy (2019-2032)
Figure 10: Age Related Macular Degeneration Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11: Age Related Macular Degeneration Epidemiology in Spain (2019-2032)
Figure 12: Age Related Macular Degeneration Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13: Age Related Macular Degeneration Epidemiology in the UK (2019-2032)
Figure 14: Age Related Macular Degeneration Diagnosed and Treatable Cases in the UK (2019-2032)
Figure 15: Age Related Macular Degeneration Epidemiology in Japan (2019-2032)
Figure 16: Age Related Macular Degeneration Diagnosed and Treatable Cases in Japan (2019-2032)
Figure 17: Drug Name, Clinical Trials by Recruitment status
Figure 18: Drug Name, Clinical Trials by Zone
Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)
Figure 20: Region-wise Market Size in USD, Million (2019-2032)
Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
Figure 22: United States Market Size in USD, Million (2019-2032)
Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)
Figure 24: Germany Market Size in USD, Million (2019-2032)
Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)
Figure 26: France Market Size in USD, Million (2019-2032)
Figure 27: France Market Size by Therapy in USD, Million (2019-2032)
Figure 28: Italy Market Size in USD, Million (2019-2032)
Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)
Figure 30: Spain Market Size in USD, Million (2019-2032)
Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)
Figure 32: United Kingdom Market Size in USD, Million (2019-2032)
Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
Figure 34: Japan Market Size in USD, Million (2019-2032)
Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)
*The list of figures is not exhaustive; the final content may vary
